
Yahoo · 29 de jul de 2026
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Últimos 170 días · 12/11/25 — 28/07/26
+30.19%
Precio de cierre en pesos argentinos. Fuente: data912.
Precio
$ 34.760
Var. %
0%
Precio LLY
US$ 1.224,98
Teórico (precio / ratio)
LLY ÷ 56
US$ 21,87
Cotización
US$ 22,74
vs teórico
+3,96%
Cotización MEP implícita
$ 1.528,58
Cotización
US$ 21,48
vs teórico
-1,8%
Cotización Cable implícita
$ 1.618,25
Sí, existe el CEDEAR de LLY (Eli Lilly and Company) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es LLY.
El ticker del CEDEAR de Eli Lilly and Company en Argentina es LLY. La acción subyacente cotiza en NYSE con el símbolo LLY.
El CEDEAR LLY tiene un ratio de 56:1. Eso significa que 56 CEDEARs equivalen a 1 acción de LLY.
El CEDEAR LLY cotiza hoy a $ 34.760 en pesos argentinos, con una variación diaria de 0%.
La acción subyacente LLY (Eli Lilly and Company) cotiza a US$ 1.224,98 en su mercado de origen (NYSE).
El precio teórico del CEDEAR LLY se calcula dividiendo el precio de LLY por el ratio (56). Hoy resulta en US$ 21,87.
En BYMA podés operar LLY en pesos, LLYD en dólar MEP y LLYC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR LLY en pesos argentinos, con datos de data912.

Yahoo · 29 de jul de 2026
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Yahoo · 29 de jul de 2026
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Yahoo · 28 de jul de 2026
Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.

Yahoo · 28 de jul de 2026
Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

Yahoo · 28 de jul de 2026
One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Yahoo · 28 de jul de 2026
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.

Yahoo · 28 de jul de 2026
The company isn't resting on its laurels.

Yahoo · 28 de jul de 2026
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Noticias vía Finnhub